Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AbbVie
Daiichi Sankyo
Imperial College London
AstraZeneca
Sahlgrenska University Hospital
pharmaand GmbH
Mario Negri Institute for Pharmacological Research
Karyopharm Therapeutics Inc
Mabwell (Shanghai) Bioscience Co., Ltd.
Kalbe International Pte. Ltd
University of Kentucky
Institut de Cancérologie de Lorraine
Health Clinics Limited
Ruhr University of Bochum
Endocyte
El Kendi Pharmaceuticals Manufacturing Company
Novartis
Canadian Cancer Trials Group
BioNumerik Pharmaceuticals, Inc.
Queensland Centre for Gynaecological Cancer
Mayo Clinic
The Cleveland Clinic
Xian-Janssen Pharmaceutical Ltd.
University of South Florida
INSYS Therapeutics Inc
Fred Hutchinson Cancer Center
European Organisation for Research and Treatment of Cancer - EORTC
Northwestern University
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Ontario Clinical Oncology Group (OCOG)
InterMune